Cargando…

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

BACKGROUND: We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund’s adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesized that T cell responses to minimal epitope peptid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Sapna P, Petroni, Gina R, Roszik, Jason, Olson, Walter C, Wages, Nolan A, Chianese-Bullock, Kimberly A, Smolkin, Mark, Varhegyi, Nikole, Gaughan, Elizabeth, Smith, Kelly T, Haden, Kathleen, Hall, Emily H, Gnjatic, Sacha, Hwu, Patrick, Slingluff, Craig L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378357/ https://www.ncbi.nlm.nih.gov/pubmed/34413169 http://dx.doi.org/10.1136/jitc-2021-003220

Ejemplares similares

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
por: Pollack, Karlyn E, et al.
Publicado: (2020)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

Defining the effects of age and gender on clinical immune response to cancer vaccination
por: Ramirez, Adriana, et al.
Publicado: (2014)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer
por: Melssen, Marit M, et al.
Publicado: (2022)

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)

A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes
por: Dillon, Patrick M, et al.
Publicado: (2013)

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
por: Dillon, Patrick M, et al.
Publicado: (2014)

IFA : la empresa competitiva sustentable en la era del capital intelectual /
por: Villarreal Arrambide, René Patricio
Publicado: (2003)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

ATLAS, Module of assembly IFAE (Barcelona)
por: ICE Serveis Audiovisuals
Publicado: (1999)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

A web tool for designing and conducting phase I trials using the continual reassessment method
por: Wages, Nolan A., et al.
Publicado: (2018)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Status of coupling compensation for the LPv3 optics in 1995
por: Verdier, A
Publicado: (1995)

Effect of lipoarabinomannan from Mycobacterium avium subsp avium in Freund's incomplete adjuvant on the immune response of cattle
por: Colavecchia, S.B., et al.
Publicado: (2012)

Atlas Tile Calorimeter submodule assembly at IFAE (Barcelona)
por: Nessi, M
Publicado: (1999)

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer
por: Dillon, Patrick M., et al.
Publicado: (2017)

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
por: Olson, Walter C, et al.
Publicado: (2011)

Incontri di Fisica delle Alte Energie (IFAE) 2014
por: Collective
Publicado: (2014)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant
por: Koh, Yi T, et al.
Publicado: (2006)

Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund’s Adjuvant, and Monophosphoryl Lipid A
por: Vitoriano-Souza, Juliana, et al.
Publicado: (2012)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

A deterministic approach for design of supervisory control of LPV systems with delay
por: Zahid, Ch. Nauman, et al.
Publicado: (2021)

Self-Scheduled LPV Control of Asymmetric Variable-Span Morphing UAV
por: Lee, Jihoon, et al.
Publicado: (2023)

14th IFAE - Incontri Sulla Fisica Della Alte Energie
por: Cacciari, M, et al.
Publicado: (2003)

Barriers and enablers for iron folic acid (IFA) supplementation in pregnant women
por: Siekmans, Kendra, et al.
Publicado: (2017)

Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
por: Jagessar, S. Anwar, et al.
Publicado: (2015)

LPV modeling of nonlinear systems: A multi‐path feedback linearization approach
por: Abbas, Hossam S., et al.
Publicado: (2021)

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
por: Schaefer , Jochen T, et al.
Publicado: (2010)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d88usqt0vu1mh1lev1p0d2bpt5